Most research peptides have a short paper trail. Thymosin alpha-1 is the exception. Its story runs back more than sixty years, starts with a gland nobody could explain, and ends with an approved drug sold in dozens of countries. Along the way it picked up a determined sequence, a chemical name, and a place in the immunology literature that few compounds of its kind can match. Here is how it got there.
A gland in search of a function
For most of the twentieth century the thymus was a puzzle. It was clearly involved in immunity, but whether it worked through hormones or simply as a nursery for cells was an open question. The work that eventually answered it began in earnest in the early 1960s in the laboratory of Abraham White at the Albert Einstein College of Medicine in New York. White and his colleagues suspected the thymus released active factors into the body, and in a 1966 paper in the Proceedings of the National Academy of Sciences they coined the term “thymosin” for these thymic-derived substances.
Naming something is not the same as isolating it. The next decade was spent chasing that activity through calf thymus tissue, batch after batch, trying to separate whatever was doing the work from everything that was not.
Fraction 5 and the search for the active molecule
By 1972 the group, now led by Allan Goldstein, had relocated to the University of Texas Medical Branch in Galveston. There they produced a partially purified calf-thymus preparation they called thymosin fraction 5. It was not a single molecule. Fraction 5 is a family of at least forty small, acidic polypeptides, and it was crude by modern standards, but it was consistent enough to scale up and test. In 1974 the team received an Investigational New Drug clearance from the FDA to study fraction 5 in children with primary immunodeficiency diseases, one of the first times a thymic preparation had been taken that far.
Fraction 5 was the haystack. The obvious next problem was to find the needle: which of those forty-odd peptides actually carried the biological activity.
1977: isolation and sequence
That answer arrived in 1977. Goldstein and colleagues purified one specific peptide out of fraction 5 and worked out its full amino acid sequence, publishing the result in the Proceedings of the National Academy of Sciences. They named it thymosin alpha-1. It is a small molecule, just 28 amino acid residues, heat-stable and highly acidic. For anyone asking who discovered thymosin alpha-1, this is the moment it stopped being a fraction and became a defined compound with a known structure.
Knowing the sequence changed everything downstream. A 28-residue peptide can be made by chemical synthesis rather than extracted from tissue, which meant researchers no longer depended on grinding up calf thymus to study it. Synthetic material could be produced to a consistent specification, and that reproducibility is what opened the door to serious clinical investigation.
From peptide to Zadaxin
The synthetic version of thymosin alpha-1 was given the generic name thymalfasin and developed as a drug under the brand Zadaxin by SciClone Pharmaceuticals. Large-scale clinical work moved forward through the 1990s, and the first international regulatory approvals followed toward the end of that decade. Zadaxin has since been approved in roughly thirty countries, including China and Italy, mainly for chronic hepatitis B and as an adjunct to vaccines in people with weakened immune responses.
Two points are worth stating plainly, because they are what separate thymosin alpha-1 from most compounds in this category. First, it has genuine approved clinical use in a number of national markets, which is rare for a research peptide. Second, it has never been approved by the FDA for any indication in the United States. Both of those facts are part of its history, and neither one should be read as guidance. The molecule is well characterised, but its regulatory standing varies sharply by country, and much of what circulates about it sits outside any approved use.
Where the record stands
What makes thymosin alpha-1 unusual is the length and clarity of its record: a named activity in 1966, a workable preparation by the early 1970s, a solved sequence in 1977, and an approved drug abroad by the end of the 1990s. That is a fuller arc than almost any peptide sold for research carries. It does not settle every open question, and plenty remain, but it does mean the science rests on decades of published, verifiable work rather than a handful of recent claims.
→ Thymosin Alpha-1 Research Guide · Thymalin Research Guide
Research use only. Vero Labs supplies thymosin alpha-1 strictly as a research compound, not for human or animal use. Every batch is independently third-party lab-tested with a published Certificate of Analysis. Nothing in this article is medical advice, a dosing recommendation, or a suggestion for use in people; it is provided for historical and scientific context only.